
|Articles|October 15, 2003
New drug developed to treat Fabry's disease
New York-Treatment is now available for Fabry's disease, a lysosomal storage disorder with ophthalmologic findings. In April, the FDA granted Orphan Drug designation for agalsidase beta (Fabrazyme, Genzyme General), an enzyme replacement therapy, for the treatment of this progressive and potentially fatal disease.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
AAO 2025: Philip J. Ferrone, MD, highlights safety and efficacy findings of gildeuretinol in Stargardt disease
2
Preclinical study suggests synaptic regeneration may offer new pathway to treat glaucoma
3
AAO 2025: The evolution of eye care on display at AAO 2025
4
AAO 2025: Trial demonstrates safety and efficacy of epithelium-on cross linking
5